NCT04033276View on ClinicalTrials.gov

IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies

PHASE4CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

January 8, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

May 3, 2022

Conditions

Renal Transplant

Interventions

DRUG

Rituximab

IV rituximab

DRUG

intravenous immune globulin

iv intravenous immune globulin

Trial Locations (2)

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

Sponsors

Collaborators (1)

GC Biopharma Corp

All Listed Sponsors

collaborator

Severance Hospital

OTHER

collaborator

GC Biopharma Corp

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT04033276 - IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies | Biotech Hunter | Biotech Hunter